

## Association between serum cholesterol and bone mineral density

Joanna Makovey<sup>a,\*</sup>, Jian Sheng Chen<sup>a</sup>, Chris Hayward<sup>b</sup>, Frances M.K. Williams<sup>c</sup>, Philip N. Sambrook<sup>a</sup>

<sup>a</sup> Institute of Bone and Joint Research, Kolling Institute, Royal North Shore Hospital, University of Sydney, Australia

<sup>b</sup> Department of Cardiology, St. Vincent's Hospital, Sydney, Australia

<sup>c</sup> Twin and Genetic Epidemiology Unit, St. Thomas' Hospital, London, UK

### ARTICLE INFO

#### Article history:

Received 29 May 2008

Revised 14 August 2008

Accepted 26 September 2008

Available online 17 October 2008

Edited by: R. Baron

#### Keywords:

Bone mineral density

Cholesterol

LDL

Triglycerides

HDL

Menopause

HRT

Body composition

### ABSTRACT

**Background:** Hypercholesterolaemia has been associated with low bone mineral density (BMD) in some but not all studies.

**Objectives:** To examine the influence of age, menopausal status and hormone replacement therapy (HRT) on the relationship between serum cholesterol and BMD in women.

**Patients and measurements:** 497 female participants (age range 20–81) comprising 224 premenopausal and 273 postmenopausal women (156 on HRT and 117 no HRT) underwent measurements of bone mineral density (BMD) and serum lipid profile.

**Results:** Total serum cholesterol (TC) and low density lipoprotein (LDL) levels were higher and lumbar spine BMD was lower in postmenopausal women not taking HRT compared to those taking HRT. TC and LDL were negatively associated with BMD at all measured sites among postmenopausal women not taking HRT in univariate regression analysis (all  $p < 0.05$ ). High density lipoprotein (HDL) had inverse relationships with BMD at all sites in pre-menopausal women and those who were exposed to HRT ( $p < 0.05$ ). In fully adjusted regression models the relationships between TC and BMD remained significant at the lumbar spine and whole body ( $p < 0.05$ ) and between LDL and lumbar spine BMD only ( $p < 0.05$ ). For subjects in the other groups, no significant associations between TC or LDL and BMD were found. Significant interactions between total cholesterol and LDL levels with HRT were detected among post-menopausal women in the regression analyses (all  $p < 0.05$ ). No such interactions were found between HDL levels and HRT.

**Conclusion:** There is a modest inverse relationship between lumbar spine and whole body BMD and serum TC and LDL levels and in post-menopausal women and HDL in pre-menopausal women. HRT use appears to modify these relationships. The mechanisms of this relationship require further study.

© 2008 Elsevier Inc. All rights reserved.

### Introduction

Hypercholesterolaemia has been associated with low bone mineral density in some [1–3] but not all [4–6] studies. A number of studies have reported a positive relationship between BMD and triglyceride levels (TG) [7,8], while the literature concerning the relationship between HDL and LDL cholesterol levels and BMD is conflicting [5,7,9–13].

For example, a study of Orozco et al. [1] found that early postmenopausal women with an atherogenic lipid profile had lower lumbar and femoral BMD and had an increased risk of osteopaenia compared to those with a normal lipid profile, suggesting that hyperlipidaemia could be associated with osteoporosis. In a longitudinal study of Tanko et al. [2] it was found that in postmenopausal women aged 50–75 years, those with the largest increases in serum cholesterol showed the greatest decreases in spine BMD independently of change in the body mass index. Contradicting these findings,

cross-sectional studies by Solomon et al. [5]; Wu et al. [6] and a prospective study of Samelson et al. [4] found no relationship between total serum cholesterol levels and BMD, but there were a number of methodological limitations in these latter studies which could affect interpretation.

The existence of a possible link between bone and metabolic pathways has been recognised for some time. Low bone mineral density has been reported to be associated with increased risk of cardiovascular mortality [14,15] and aortic calcification [3,16,17], however, the pathophysiologic mechanisms underlying this association are unknown. A longitudinal study reported that in early postmenopausal women, each decrease of one standard deviation (SD) in distal forearm bone mineral content was associated with a 2.3-fold increased risk for cardiovascular death within the next 17 years. This study also estimated that in 70 year old women, a one SD decrease in their BMD Z-score was associated with a 1.8-fold increase of cardiovascular death [15]. It was suggested that low bone mass during menopause could be a risk factor for increased cardiovascular mortality in later life [15]. Similarly in the Study of Osteoporotic Fractures (SOF), each one SD decrease of BMD in the proximal radius

\* Corresponding author.

E-mail address: [jmakovey@med.usyd.edu.au](mailto:jmakovey@med.usyd.edu.au) (J. Makovey).

was associated with a relative risk of 1.7 for stroke death in older postmenopausal women [14,18]. In this study, the association was not confounded by history of previous stroke, hypertension, postmenopausal use of oestrogen, thiazide use, diabetes mellitus or smoking [14].

The aim of the present study was to examine the relationship between cholesterol levels and bone mineral density at various skeletal sites. Moreover, we sought to specifically examine whether or not such relationships are affected by age, menopausal status or HRT use.

## Materials and methods

### Subjects

Study subjects were healthy adult twin pairs aged >18 years recruited as part of the Northern Sydney Twin Study at the Department of Rheumatology of the Royal North Shore Hospital. Subjects taking hormone replacement therapy (HRT) were not excluded, but such use was recorded. Women who have ever taken HRT for more than 6 months within the last 2 years were considered as HRT-users. Participants, who had been taking statins, ezetimibe, gemfibrozil, fenofibrate, sterol binding agents, SERMs and bisphosphonates recently (within the last 12 months) or ever for more than 6 months were excluded from the study analyses. The hospital's Human Research Ethics Committee approved the study. Some of these twin data have been previously reported [19–21]. After providing written informed consent, each twin was interviewed separately in accordance with a standard questionnaire to collect demographic, lifestyle and medical history data.

Baseline characteristics included age, height (m), weight (kg), BMI (weight/height<sup>2</sup>, kg/m<sup>2</sup>), smoking history, alcohol consumption and menopausal status for women.

Fasting serum total cholesterol (TC), high density lipoprotein (HDL), and triglycerides (TG) were measured and low density lipoprotein (LDL) levels were calculated using standard formula: LDL=TC-HDL-(TG/5) [22].

### Bone mineral density and body composition measurements

Whole body, lumbar spine (L1–L4) and hip sites were scanned by fan-beam dual-energy X-ray absorptiometry (DEXA) using a QDR 4500 W (Hologic, Waltham, MA, USA). Bone mineral density (BMD) of the whole body (WB), lumbar spine (LS), total hip (HIPTOT) and femoral neck (FN) were obtained from DEXA scans using standard protocols as previously described [19,23]. The results were given in g/cm<sup>2</sup>.

Body composition measures, such as total fat mass (TOT FM) and total lean mass (TOT LM) were obtained directly from the body composition analysis of a whole body DEXA scan (kg). All scans were analysed by same operator.

### Statistical analysis

A significant interaction of cholesterol with HRT was detected among post-menopausal women in the regression analysis of relationship between cholesterol and BMD at different skeletal sites (all  $p < 0.05$ ). Therefore, the study population was divided into three groups: pre-menopausal women, or post-menopausal women who were either using or not using HRT. *T*-tests were used for comparing differences in cholesterol and BMD between groups. Pearson correlations were used to examine the relationship between BMD measures and cholesterol. Linear regression analysis was performed to examine the strength of these relationships after adjusting for potential confounders such as age, BMI, body fat mass, smoking history and alcohol intake. Lack of independence among twin family members was taken into account by excluding one of the members of the MZ twin pairs and using Generalized Estimating Equations (GEE). *P* values of <0.05 were considered significant. All statistical analyses were performed using SPSS for Windows 11.5 (SPSS, Chicago, IL) and Stata 8.2.

## Results

There were 556 female twin participants (278 pairs, age range 20 to 81 years) in the study. After randomly excluding one member of

**Table 1**  
Baseline characteristics of study population

| Mean (SD)                                 | Women post-menopausal no HRT (N=117) | Women post-menopausal on HRT (N=156) | Women pre-menopausal (N=224) | <i>p</i> *  | <i>p</i> ** |
|---|--------------------------------------|--------------------------------------|------------------------------|-------------|-------------|
| Age (years)                               | 58.48 (8.72)                         | 57.92 (7.12)                         | 35.81 (9.24)                 | $p < 0.001$ | 0.11        |
| Weight (kg)                               | 76.45 (12.27)                        | 75.99 (10.88)                        | 71.56 (11.31)                | $p < 0.001$ | 0.74        |
| Height (m)                                | 1.60 (0.06)                          | 1.62 (0.06)                          | 1.65 (0.06)                  | $p < 0.001$ | 0.05        |
| BMI (kg/m <sup>2</sup> )                  | 29.83 (5.16)                         | 29.09 (4.47)                         | 26.37 (4.44)                 | $p < 0.001$ | 0.20        |
| Total cholesterol (mmol/l)                | 6.04 (1.01)                          | 5.85 (0.97)                          | 5.14 (0.91)                  | $p < 0.001$ | 0.13        |
| LDL (mmol/l)                              | 4.45 (1.06)                          | 4.29 (1.07)                          | 3.61 (0.96)                  | $p < 0.001$ | 0.25        |
| Triglycerides (mmol/l)                    | 1.51 (0.88)                          | 1.54 (0.69)                          | 1.21 (0.74)                  | $p < 0.001$ | 0.72        |
| HDL (mmol/l)                              | 1.31 (0.51)                          | 1.27 (0.59)                          | 1.33 (0.41)                  | 0.67        | 0.52        |
| <i>BMD (g/cm<sup>2</sup>)</i>             |                                      |                                      |                              |             |             |
| Lumbar spine (L1–L4) (g/cm <sup>2</sup> ) | 0.944 (0.153)                        | 0.958 (0.144)                        | 1.047 (0.114)                | $p < 0.001$ | 0.45        |
| Total hip (g/cm <sup>2</sup> )            | 0.902 (0.120)                        | 0.892 (0.131)                        | 0.970 (0.122)                | $p < 0.001$ | 0.50        |
| Femoral neck (g/cm <sup>2</sup> )         | 0.759 (0.119)                        | 0.750 (0.121)                        | 0.849 (0.116)                | $p < 0.001$ | 0.53        |
| Whole body (g/cm <sup>2</sup> )           | 1.061 (0.116)                        | 1.080 (0.109)                        | 1.147 (0.095)                | $p < 0.001$ | 0.16        |
| <i>Body composition</i>                   |                                      |                                      |                              |             |             |
| Total fat mass (kg)                       | 26.21 (9.42)                         | 24.57 (8.57)                         | 20.55 (9.26)                 | $p < 0.001$ | 0.13        |
| Total lean mass (kg)                      | 38.77 (4.55)                         | 39.27 (4.67)                         | 41.41 (4.89)                 | $p < 0.001$ | 0.38        |
| <i>Smoking</i>                            |                                      |                                      |                              |             |             |
| Never smoked                              | 78                                   | 86                                   | 136                          |             |             |
| Ever smoked                               | 39                                   | 70                                   | 88                           |             |             |
| <i>Alcohol consumption</i>                |                                      |                                      |                              |             |             |
| Light (<5 units per week)                 | 96                                   | 114                                  | 176                          |             |             |
| Moderate (6–15 units per week)            | 18                                   | 38                                   | 41                           |             |             |
| Heavy (more than 15 units per week)       | 3                                    | 4                                    | 7                            |             |             |

*p*\* – *p*-values for the results of *T*-test between post-menopausal women with no HRT history and premenopausal women.

*p*\*\* – *p*-values for the results of *T*-test between post-menopausal women with no HRT history and post-menopausal women on HRT.

**Table 2**  
Correlations between serum cholesterol and bone mineral density at various skeletal sites

|                  | Post-menopausal women no HRT (n=117) |      | Post-menopausal women on HRT (n=156) |      | Pre-menopausal women (n=224) |      |
|------------------|--------------------------------------|------|--------------------------------------|------|------------------------------|------|
|                  | r                                    | P    | r                                    | P    | r                            | P    |
| Lumbar spine BMD | -0.20                                | 0.03 | -0.002                               | 0.99 | 0.06                         | 0.34 |
| Total hip BMD    | -0.12                                | 0.20 | -0.003                               | 0.97 | 0.005                        | 0.94 |
| Femoral neck BMD | -0.14                                | 0.13 | -0.01                                | 0.90 | 0.02                         | 0.79 |
| Whole body BMD   | -0.21                                | 0.02 | -0.06                                | 0.47 | 0.05                         | 0.48 |

each MZ twin pair ( $n=27$ ), subjects taking cholesterol lowering therapy (28) and bisphosphonates (8), there were 497 women left for the final analyses, comprising 224 premenopausal and 273 postmenopausal women (156 on HRT and 117 no HRT).

The characteristics of the subjects according to these three groups are shown in Table 1. Post-menopausal women, who have never taken HRT, had significantly higher cholesterol levels than post-menopausal women on HRT or pre-menopausal women (6.04 vs. 5.85, and 5.14 mmol/l, respectively,  $p<0.001$ ). Serum LDL and triglycerides levels were also elevated in this study group ( $p<0.001$ ). They also had lower BMD measurements at the lumbar spine compare to the other study groups (0.94, 0.96 and 1.05 g/cm<sup>2</sup>, respectively;  $p<0.001$ ). HDL levels were similar for all sub-groups of participants. Fat mass was higher in postmenopausal women not taking HRT than those taking HRT and premenopausal women (26.21, 24.57 and 20.55 kg, respectively;  $p<0.001$ ) and lean mass was higher in premenopausal women ( $p<0.001$ ). There was no significant difference in age between postmenopausal women who had never taken or those who had taken HRT (58.5 vs 57.9 years).

The correlations between total cholesterol and BMD at various sites are shown in Table 2. BMD at the lumbar spine and whole body showed statistically significant inverse correlations with total cholesterol level but only in post-menopausal women who had never taken HRT ( $r=-0.236$  and  $r=-0.246$ ,  $p<0.05$ , for lumbar spine and whole body, respectively). Fig. 1 shows these relationships for the three groups at the lumbar spine site.


Regression analyses for total cholesterol, LDL and HDL levels and bone mineral density at different skeletal sites were performed. The results of univariate analyses presented in Table 3 and multivariate fully adjusted regression models presented in Table 4. Total serum cholesterol was negatively associated with BMD at all sites among postmenopausal women not taking HRT in univariate regression analysis (all  $p<0.05$ ). Similar results were found for LDL ( $p<0.05$ ). HDL levels on the other hand had significant inverse relationships with BMD at all skeletal sites in pre-menopausal women and those who were exposed to HRT ( $p<0.05$ , except for LSBMD/HDL in postmenopausal women on HRT) (Table 3). In the fully adjusted regression analysis the relationships between total serum cholesterol and BMD remained significant for the same group of study subjects at the lumbar spine and whole body ( $p<0.05$ ) and between LDL and BMD at the lumbar spine only ( $p<0.001$ ) (Table 4). Using the total fat mass instead of BMI in the regression models did not alter the results (data not shown). For subjects in the other groups, no significant association between total serum cholesterol or LDL and BMD was detected. Nor was there found a relationship between serum triglycerides and BMD at any skeletal site for all studied sub-groups of women. The inverse relationships between HDL and BMD remained statistically significant in fully adjusted models for lumbar spine and hip BMD measures in postmenopausal women not taking HRT and lumbar spine and whole body BMD in premenopausal women.

## Discussion


In univariate analyses, higher total cholesterol level was significantly associated with lower BMD at lumbar spine and whole body in

postmenopausal women not taking HRT. Moreover, in fully adjusted regression models, the relationship between total cholesterol and BMD remained significant in post-menopausal women who had never


Post-menopausal women, no HRT ( $r = -0.200$ ;  $p < 0.05$ )



Post-menopausal women, on HRT ( $r = -0.002$ ;  $p = 0.99$ )



Pre-menopausal women ( $r = 0.060$ ;  $p = 0.34$ )



**Fig. 1.** Correlations between total serum cholesterol and Lumbar spine BMD in Post-menopausal women, no HRT ( $r=-0.200$ ;  $p<0.05$ ) Post-menopausal women, on HRT ( $r=-0.002$ ;  $p=0.99$ ) Pre-menopausal women ( $r=0.060$ ;  $p=0.34$ ).

**Table 3**

Results of the univariate regression analysis for total serum cholesterol, LDL, triglycerides and HDL and bone mineral density at various skeletal sites (unadjusted)

|  | Post-menopausal women no HRT |              | Post-menopausal women on HRT |              | Pre-menopausal women    |              |
|--|------------------------------|--------------|------------------------------|--------------|-------------------------|--------------|
|  | B (95% CI)                   | P            | B (95% CI)                   | P            | B (95% CI)              | P            |
| <i>Lumbar spine BMD (g/cm<sup>2</sup>)</i> | (n=117)                      |              | (n=156)                      |              | (n=224)                 |              |
| Tot cholesterol (mmol/l)                   | -0.036 (-0.06– -0.012)       | <b>0.004</b> | 0.003 (-0.018–0.023)         | 0.808        | 0.008 (-0.008–0.024)    | 0.298        |
|  | (n=105)                      |              | (n=144)                      |              | (n=202)                 |              |
| LDL (mmol/l)                               | -0.033 (-0.058– -0.009)      | <b>0.008</b> | 0.009 (-0.013–0.030)         | 0.427        | 0.015 (-0.007–0.031)    | 0.061        |
| Triglycerides (mmol/l)                     | -0.026 (-0.057–0.006)        | 0.112        | 0.031 (-0.019–0.064)         | 0.064        | 0.011 (-0.003–0.026)    | 0.127        |
| HDL (mmol/l)                               | -0.012 (-0.060–0.037)        | 0.639        | -0.036 (-0.073–0.022)        | 0.065        | -0.056 (-0.092– -0.017) | <b>0.005</b> |
| <i>Total hip BMD (g/cm<sup>2</sup>)</i>    | (n=117)                      |              | (n=156)                      |              | (n=224)                 |              |
| Tot cholesterol (mmol/l)                   | -0.018 (-0.036– -0.001)      | <b>0.036</b> | 0.001 (-0.015–0.017)         | 0.912        | 0.002 (-0.016–0.020)    | 0.810        |
|  | (n=105)                      |              | (n=144)                      |              | (n=202)                 |              |
| LDL (mmol/l)                               | -0.018 (-0.036–0.00003)      | <b>0.050</b> | 0.012 (-0.005–0.028)         | 0.161        | 0.010 (-0.007–0.026)    | 0.246        |
| Triglycerides (mmol/l)                     | -0.005 (-0.028–0.018)        | 0.668        | 0.020 (-0.016–0.057)         | 0.279        | 0.023 (0.002–0.044)     | <b>0.031</b> |
| HDL (mmol/l)                               | -0.011 (-0.055–0.032)        | 0.608        | -0.038 (-0.067– -0.009)      | <b>0.010</b> | -0.038 (-0.074– -0.028) | <b>0.034</b> |
| <i>Femoral neck BMD (g/cm<sup>2</sup>)</i> | (n=117)                      |              | (n=156)                      |              | (n=224)                 |              |
| Tot cholesterol (mmol/l)                   | -0.023 (-0.040– -0.006)      | <b>0.007</b> | -0.001 (-0.017–0.016)        | 0.950        | 0.003 (-0.015–0.020)    | 0.766        |
|  | (n=105)                      |              | (n=144)                      |              | (n=202)                 |              |
| LDL (mmol/l)                               | -0.021 (-0.039– -0.003)      | <b>0.026</b> | 0.012 (-0.004–0.027)         | 0.144        | 0.010 (-0.006–0.026)    | 0.207        |
| Triglycerides (mmol/l)                     | -0.010 (-0.032–0.011)        | 0.339        | 0.019 (-0.015–0.053)         | 0.285        | 0.014 (-0.003–0.032)    | 0.096        |
| HDL (mmol/l)                               | -0.009 (-0.052–0.035)        | 0.696        | -0.045 (-0.072– -0.018)      | <b>0.001</b> | -0.046 (-0.081– -0.011) | <b>0.009</b> |
| <i>Whole body BMD (g/cm<sup>2</sup>)</i>   | (n=117)                      |              | (n=156)                      |              | (n=224)                 |              |
| Tot cholesterol (mmol/l)                   | -0.028 (-0.045– -0.012)      | <b>0.001</b> | -0.003 (-0.018–0.013)        | 0.726        | 0.004 (-0.009–0.017)    | 0.516        |
|  | (n=105)                      |              | (n=144)                      |              | (n=202)                 |              |
| LDL (mmol/l)                               | -0.030 (-0.048– -0.012)      | <b>0.001</b> | 0.005 (-0.011– -0.021)       | 0.549        | 0.010 (-0.003–0.022)    | 0.142        |
| Triglycerides (mmol/l)                     | -0.033 (-0.054– -0.012)      | <b>0.002</b> | 0.014 (-0.011–0.039)         | 0.275        | 0.011 (-0.005–0.026)    | 0.191        |
| HDL (mmol/l)                               | 0.025 (-0.018–0.067)         | 0.262        | -0.033 (-0.062– -0.005)      | <b>0.020</b> | -0.035 (-0.067– -0.036) | <b>0.029</b> |

taken HRT. This was not seen in premenopausal women or in post-menopausal women taking HRT. Similar results were reported by the large study of Solomon and colleagues of subjects participating in the NHANES survey [5]. They found that the association between total cholesterol and BMD observed in unadjusted analyses was no longer present in fully adjusted models. However the pooling of data for final analyses in the study of Solomon et al. [5] included both genders, a wide age range and pre- and post-menopausal women, regardless of HRT use. Our study suggests HRT use could modify relationship

between total cholesterol level and BMD among post-menopausal women, which needs to be accounted for in any statistical analysis.

Previous studies of the relationship between BMD and serum cholesterol have been conflicting. Orozco et al. [1] studied 52 obese, early menopausal women (mean age 55 years) with no history of HRT use and found that 29 women with hypercholesterolaemia (defined as >240 mg/dl) had a higher prevalence of low BMD at the spine (83% vs 55%) and femoral neck 96.5% vs 38%) than 23 women without hypercholesterolaemia. Samelson et al. [4] measured serum

**Table 4**

Results of the multiple regression analysis for total serum cholesterol, HDL and LDL and bone mineral density at various skeletal sites

|  | Post-menopausal women no HRT |                  | Post-menopausal women on HRT |              | Pre-menopausal women    |              |
|--|------------------------------|------------------|------------------------------|--------------|-------------------------|--------------|
|  | B (95% CI)                   | P                | B (95% CI)                   | P            | B (95% CI)              | P            |
| <i>Lumbar spine BMD (g/cm<sup>2</sup>)</i> | (n=117)                      |                  | (n=156)                      |              | (n=224)                 |              |
| Total cholesterol (mmol/l)                 | -0.030 (-0.057– -0.004)      | <b>0.023</b>     | 0.013 (-0.008–0.034)         | 0.214        | 0.004 (-0.012–0.021)    | 0.610        |
|  | (n=105)                      |                  | (n=144)                      |              | (n=202)                 |              |
| LDL (mmol/l)                               | -0.044 (-0.076– -0.011)      | <b>0.009</b>     | 0.009 (-0.014–0.032)         | 0.452        | 0.005 (-0.013–0.024)    | 0.574        |
| Triglycerides (mmol/l)                     | -0.007 (-0.046–0.032)        | 0.722            | 0.009 (-0.029–0.047)         | 0.654        | 0.005 (-0.025–0.015)    | 0.613        |
| HDL (mmol/l)                               | -0.119 (-0.179–0.058)        | <b>&lt;0.001</b> | -0.018 (-0.061–0.024)        | 0.399        | -0.061 (-0.112– -0.010) | <b>0.020</b> |
| <i>Total hip BMD (g/cm<sup>2</sup>)</i>    | (n=117)                      |                  | (n=156)                      |              | (n=224)                 |              |
| Total cholesterol (mmol/l)                 | -0.012 (-0.031–0.006)        | 0.190            | 0.006 (-0.010–0.021)         | 0.474        | -0.0002 (-0.018–0.018)  | 0.984        |
|  | (n=105)                      |                  | (n=144)                      |              | (n=202)                 |              |
| LDL (mmol/l)                               | -0.018 (-0.044–0.008)        | 0.183            | 0.011 (-0.007–0.030)         | 0.236        | -0.00004 (-0.019–0.019) | 0.996        |
| Triglycerides (mmol/l)                     | -0.005 (-0.041–0.031)        | 0.794            | -0.023 (-0.063–0.017)        | 0.260        | 0.014 (-0.014–0.042)    | 0.319        |
| HDL (mmol/l)                               | -0.043 (-0.084–0.002)        | <b>0.041</b>     | -0.018 (-0.049–0.012)        | 0.241        | -0.031 (-0.081–0.018)   | 0.217        |
| <i>Femoral neck BMD (g/cm<sup>2</sup>)</i> | (n=117)                      |                  | (n=156)                      |              | (n=224)                 |              |
| Total cholesterol (mmol/l)                 | -0.011 (-0.027–0.004)        | 0.158            | 0.005 (-0.012–0.021)         | 0.592        | 0.002 (-0.015–0.020)    | 0.807        |
|  | (n=105)                      |                  | (n=144)                      |              | (n=202)                 |              |
| LDL (mmol/l)                               | -0.015 (-0.040–0.010)        | 0.250            | 0.008 (-0.010–0.025)         | 0.880        | 0.002 (-0.015–0.020)    | 0.790        |
| Triglycerides (mmol/l)                     | 0.0003 (-0.033–0.034)        | 0.986            | -0.017 (-0.054–0.020)        | 0.369        | 0.004 (-0.017–0.026)    | 0.702        |
| HDL (mmol/l)                               | -0.052 (-0.091–0.013)        | <b>0.009</b>     | -0.034 (-0.064– -0.005)      | <b>0.024</b> | -0.048 (-0.097–0.0004)  | 0.052        |
| <i>Whole body BMD (g/cm<sup>2</sup>)</i>   | (n=117)                      |                  | (n=156)                      |              | (n=224)                 |              |
| Total cholesterol (mmol/l)                 | -0.022 (-0.040– -0.004)      | <b>0.018</b>     | 0.004 (-0.012–0.019)         | 0.634        | 0.003 (-0.011–0.016)    | 0.703        |
|  | (n=105)                      |                  | (n=144)                      |              | (n=202)                 |              |
| LDL (mmol/l)                               | -0.022 (-0.046–0.001)        | 0.061            | 0.003 (-0.013–0.020)         | 0.708        | 0.003 (-0.011–0.018)    | 0.668        |
| Triglycerides (mmol/l)                     | -0.010 (-0.041–0.021)        | 0.545            | -0.007 (-0.037–0.022)        | 0.625        | 0.003 (-0.015– -0.002)  | 0.751        |
| HDL (mmol/l)                               | -0.036 (-0.084–0.011)        | 0.132            | -0.030 (-0.060–0.001)        | 0.057        | -0.041 (-0.081– -0.002) | <b>0.039</b> |

Total cholesterol— Adjusted for age, BMI, smoking and alcohol consumption.

LDL— Adjusted for age, BMI, HDL, Triglycerides, smoking and alcohol consumption.

HDL— Adjusted for age, BMI, LDL, Triglycerides, smoking and alcohol consumption.

cholesterol in 1953–55 in 712 women and 450 men enrolled in the Framingham study. Bone density was not measured until 34 years later (1988–1989). Cross-sectional BMD was similar across quartiles of total cholesterol in both men and women, except for radial shaft BMD in men, which was lower with increasing cholesterol. Mean duration of oestrogen use was two years in women but it was unclear how many women actually used oestrogen and when this was prescribed, although since the mean age at baseline was 41.3 years, presumably some use of the oestrogen was premenopausal or for oral contraceptive purposes. Current use of HRT at the time of BMD measurement was not specified.

We have not found any association between total cholesterol and BMD in post-menopausal women who had a history of HRT use and this may be because HRT use affects the relationship by modifying total cholesterol levels. Most other previous studies of the effect of HRT on plasma lipids have reported that oestrogen use lowers LDL cholesterol and increases HDL cholesterol [24–26], although the effects on total cholesterol have not been reported. Thomsen et al. [27] performed a post hoc analysis of 133 postmenopausal women who had participated in a randomised trial of varying doses of oestradiol plus gestodene versus placebo over 3 years. Although BMD increases at the spine and hip correlated with reductions in total cholesterol, endogenous serum cholesterol was high at baseline (6.70 mmol/l) and not associated with BMD of the spine and hip. A positive association has also been reported between the severity of carotid atherosclerosis, serum cholesterol and low total body BMD in older postmenopausal women [3]. In asymptomatic postmenopausal women, those with lumbar osteoporosis have higher coronary calcium scores (indicative of atherosclerosis) than those with normal bone density [16].

Our study is consistent with the study of Tanko et al. [2] which found a significant inverse correlation between serum cholesterol at the spine but not the hip in 340 postmenopausal Danish women at baseline. Moreover when followed over 8 years, those women with the largest increases in serum cholesterol showed the greatest decreases in BMD. It is unclear if any women started HRT during the follow-up period of this study. The authors concluded this relationship was due to oestrogen deficiency rather than any direct influence of serum cholesterol on osteoblast function.

However in vitro and in vivo studies indicate that cholesterol and its metabolites can influence the functional activity of osteoblasts [28,29]. In mice and rabbits fed with atherogenic high-fat diet reduced bone mineralization was observed [30]. In addition, some [31–37], but not all [38,39] studies have suggested that statins, widely used as lipid-lowering agents, offer benefits in the preservation of bone mass and the prevention of osteoporotic fractures. Why such an effect would be evident in the spine but not the hip remains unclear, however the relative composition in terms of trabecular versus cortical bone varies at these sites and we and others have previously reported this differential effect on other bone related endpoints. For example we have shown that total body fat mass is related to lumbar spine BMD but not hip BMD in younger subjects [20].

Our study has several strengths and limitations. We measured a large number of subjects in a variety of menopausal groupings. However we only measured total cholesterol in all of the study participants. The numbers of subjects who had cholesterol sub-fractions measured such as triglycerides, HDL or LDL, were smaller. Our study did not confirm a positive relationship between BMD and triglyceride levels reported earlier [7,40]. The literature concerning relationships between HDL and LDL cholesterol levels and BMD is also conflicting [5,7,12,13,41–44]. For example, D'Amelio et al. [45] reported a significant inverse relationship between BMD and HDL in postmenopausal women but not with total cholesterol or LDL. Cui et al. [7] observed an inverse relationship between LDL and hip but not spine BMD in postmenopausal women, however the effect of HRT was not examined. Poli et al. [12] found no relationship between BMD and

HDL and total cholesterol but one between LDL and spinal BMD, but again the effect of HRT was not examined. Aside from genetic differences, one possible explanation for these differences may be the importance of oestrogen concentration in these groups. Most studies have explored relationships in post-menopausal women, but time since menopause varies considerably between groups in the different studies which have taken varying approaches to HRT, some excluding any women on such therapy. By having pre-menopausal, post-menopausal women on HRT and post-menopausal women with no HRT history in three separate study groups, our study was uniquely able to address the effect of HRT on this relationship. Accordingly the relationship between cholesterol sub-fractions and BMD at different sites clearly needs further study.

In conclusion, we observed a modest inverse relationship between lumbar spine and whole body BMD and total serum cholesterol and LDL levels and hip BMD measurements and HDL in post-menopausal women. HRT use appears to act to reverse these relationships and needs to be taken into account in future studies. Because oestrogen can have direct effects on bone and cholesterol metabolism, the mechanisms of the relationship requires further evaluation.

### Acknowledgments

We would like to thank the Lincoln Centre for Research into Bone and Joint Disease and Osteoporosis Australia for supporting this project.

### References

- [1] Orozco P. Atherogenic lipid profile and elevated lipoprotein (a) are associated with lower bone mineral density in early postmenopausal overweight women. *Eur J Epidemiol* 2004;19:1105–12.
- [2] Tanko LB, Bagger YZ, Nielsen SB, Christiansen C. Does serum cholesterol contribute to vertebral bone loss in postmenopausal women? *Bone* 2003;32:8–14.
- [3] Uyama O, Yoshimoto Y, Yamamoto Y, Kawai A. Bone changes and carotid atherosclerosis in postmenopausal women. *Stroke* 1997;28:1730–2.
- [4] Samelson EJ, Cupples LA, Hannan MT, Wilson PW, Williams SA, Vaccarino V, et al. Long-term effects of serum cholesterol on bone mineral density in women and men: the Framingham Osteoporosis Study. *Bone* 2004;34:557–61.
- [5] Solomon DH, Avorn J, Canning CF, Wang PS. Lipid levels and bone mineral density. *Am J Med* 2005;118:1414.
- [6] Wu LY, Yang TC, Kuo SW, Hsiao CF, Hung YJ, Hsieh CH, et al. Correlation between bone mineral density and plasma lipids in Taiwan. *Endocr Res* 2003;29:317–25.
- [7] Cui LH, Shin MH, Chung EK, Lee YH, Kweon SS, Park KS, et al. Association between bone mineral densities and serum lipid profiles of pre- and post-menopausal rural women in South Korea. *Osteoporos Int* 2005;16:1975–81.
- [8] Dennison EM, Syddall HE, Aihie SA, Martin HJ, Cooper C. Lipid profile, obesity and bone mineral density: the Hertfordshire Cohort Study. *QJM* 2007;100:297–303.
- [9] Brownbill RA, Ilich JZ. Lipid profile and bone paradox: higher serum lipids are associated with higher bone mineral density in postmenopausal women. *J Womens Health (Larchmt)* 2006;15:261–70.
- [10] D'Amelio P, Pescarmona GP, Gariboldi A, Isaia GC. High density lipoproteins (HDL) in women with postmenopausal osteoporosis: a preliminary study. *Menopause* 2001;8:429–32.
- [11] D'Amelio P, Di BS, Tamone C, Ravazzoli MG, Cristofaro MA, Di SM, et al. HDL cholesterol and bone mineral density in normal-weight postmenopausal women: is there any possible association? *Panminerva Med* 2008;50:89–96.
- [12] Poli A, Bruschi F, Cesana B, Rossi M, Paoletti R, Crosignani PG. Plasma low-density lipoprotein cholesterol and bone mass densitometry in postmenopausal women. *Obstet Gynecol* 2003;102:922–6.
- [13] Yamaguchi T, Sugimoto T, Yano S, Yamauchi M, Sowa H, Chen Q, et al. Plasma lipids and osteoporosis in postmenopausal women. *Endocr J* 2002;49:211–7.
- [14] Browner WS, Seeley DG, Vogt TM, Cummings SR. Non-trauma mortality in elderly women with low bone mineral density. Study of Osteoporotic Fractures Research Group. *Lancet* 1991;338:355–8.
- [15] Von der Recke P, Hansen MA, Hassager C. The association between low bone mass at the menopause and cardiovascular mortality. *Am J Med* 1999;106:273–8.
- [16] Barendolts EI, Berman M, Kukreja SC, Kouznetsova T, Lin C, Chomka EV. Osteoporosis and coronary atherosclerosis in asymptomatic postmenopausal women. *Calcif Tissue Int* 1998;62:209–13.
- [17] Kiel DP, Kauppila LI, Cupples LA, Hannan MT, O'Donnell CJ, Wilson PW. Bone loss and the progression of abdominal aortic calcification over a 25 year period: the Framingham Heart Study. *Calcif Tissue Int* 2001;68:271–6.
- [18] Browner WS, Pressman AR, Nevitt MC, Cauley JA, Cummings SR. Association between low bone density and stroke in elderly women. The study of osteoporotic fractures. *Stroke* 1993;24:940–6.

- [19] Naganathan V, Macgregor A, Snieder H, Nguyen T, Spector T, Sambrook P. Gender differences in the genetic factors responsible for variation in bone density and ultrasound. *J Bone Miner Res* 2002;17:725–33.
- [20] Makovey J, Naganathan V, Sambrook P. Gender differences in relationships between body composition components, their distribution and bone mineral density: a cross-sectional opposite sex twin study. *Osteoporos Int* 2005;16:1495–505.
- [21] Makovey J, Nguyen TV, Naganathan V, Wark JD, Sambrook PN. Genetic effects on bone loss in peri- and postmenopausal women: a longitudinal twin study. *J Bone Miner Res* 2007;22:1773–80.
- [22] Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* 1972;18:499–502.
- [23] Naganathan V, Sambrook P. Gender differences in volumetric bone density: a study of opposite-sex twins. *Osteoporos Int* 2003;14:564–9.
- [24] Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. *JAMA* 1998;280:605–13.
- [25] Darling GM, Johns JA, McCloud PI, Davis SR. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. *N Engl J Med* 1997;337:595–601.
- [26] Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. *N Engl J Med* 2000;343:522–9.
- [27] Thomsen AB, Silvestri S, Haarbo J, Christiansen C, Bjarnason NH. Associated response in bone and lipids during hormone replacement therapy. *Maturitas* 2004;47:39–45.
- [28] Parhami F, Morrow AD, Balucan J, Leitinger N, Watson AD, Tintut Y, et al. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. *Arterioscler Thromb Vasc Biol* 1997;17:680–7.
- [29] Parhami F, Garfinkel A, Demer LL. Role of lipids in osteoporosis. *Arterioscler Thromb Vasc Biol* 2000;20:2346–8.
- [30] Parhami F, Tintut Y, Beamer WG, Gharavi N, Goodman W, Demer LL. Atherogenic high-fat diet reduces bone mineralization in mice. *J Bone Miner Res* 2001;16:182–8.
- [31] Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, et al. Stimulation of bone formation in vitro and in rodents by statins. *Science* 1999;286:1946–9.
- [32] Edwards CJ, Hart DJ, Spector TD. Oral statins and increased bone-mineral density in postmenopausal women. *Lancet* 2000;355:2218–9.
- [33] Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H. Statin drugs and the risk of fracture. *JAMA* 2000;284:1921–2.
- [34] Garrett IR, Gutierrez G, Mundy GR. Statins and bone formation. *Curr Pharm Des* 2001;7:715–36.
- [35] Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H. Statins and fracture risk. *JAMA* 2001;286:669–70.
- [36] Mundy GR. Statins and their potential for osteoporosis. *Bone* 2001;29:495–7.
- [37] Garrett IR, Mundy GR. The role of statins as potential targets for bone formation. *Arthritis Res* 2002;4:237–40.
- [38] Reid IR, Hague W, Emberson J, Baker J, Tonkin A, Hunt D, et al. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term intervention with pravastatin in ischaemic disease. *Lancet* 2001;357:509–12.
- [39] van Staa TP, Wegman S, de Vries F, Leufkens B, Cooper C. Use of statins and risk of fractures. *JAMA* 2001;285:1850–5.
- [40] Dennison EM, Syddall HE, Aihie SA, Martin HJ, Cooper C. Lipid profile, obesity and bone mineral density: the Hertfordshire Cohort Study. *QJM* 2007;100:297–303.
- [41] Brownbill RA, Ilich JZ. Lipid profile and bone paradox: higher serum lipids are associated with higher bone mineral density in postmenopausal women. *J Womens Health (Larchmt)* 2006;15:261–70.
- [42] D'Amelio P, Pescarmona GP, Gariboldi A, Isaia GC. High density lipoproteins (HDL) in women with postmenopausal osteoporosis: a preliminary study. *Menopause* 2001;8:429–32.
- [43] D'Amelio P, Di BS, Tamone C, Ravazzoli MG, Cristofaro MA, Di SM, et al. HDL cholesterol and bone mineral density in normal-weight postmenopausal women: is there any possible association? *Panminerva Med* 2008;50:89–96.
- [44] Adami S, Braga V, Zamboni M, Gatti D, Rossini M, Bakri J, et al. Relationship between lipids and bone mass in 2 cohorts of healthy women and men. *Calcif Tissue Int* 2004;74:136–42.
- [45] D'Amelio P, Pescarmona GP, Gariboldi A, Isaia GC. High density lipoproteins (HDL) in women with postmenopausal osteoporosis: a preliminary study. *Menopause* 2001;8:429–32.